NeoGenomics reports Q2 adjusted EPS 3c, consensus 2c

Reports Q2 revenue $181.33M, consensus $182.64M. “In the second quarter clinical revenue increased by 16% driven by sequential improvement in AUP, a record quarter for volumes, and NGS growth of 23%,” said Tony Zook, CEO of NeoGenomics (NEO). “Strength in our Clinical business was largely offset by continuing pressure in pharma revenue that was beyond our initial assumptions, and a delay in our commercial launch of PanTracer(TM) Liquid Biopsy that impacted our expected NGS revenue.”